Stock Watch: The Two Sides Of A Complete Response Letter
Acadia Comes Out Guns Blazing While The FDA’s Hands Are Tied
The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.
